295 related articles for article (PubMed ID: 26732883)
41. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
[TBL] [Abstract][Full Text] [Related]
42. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.
Akhtar S; Rauf MS; Khafaga Y; Al-Kofide A; Elhassan TAM; Elshenawy MA; Nadri J; Mushtaq AH; Bakshi N; Shamayel M; Al-Sweedan S; Sarwar S; Maghfoor I
BMC Cancer; 2021 Apr; 21(1):351. PubMed ID: 33794818
[TBL] [Abstract][Full Text] [Related]
43. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
Gloghini A; Bosco A; Ponzoni M; Spina M; Carbone A
Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
[TBL] [Abstract][Full Text] [Related]
44. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
Chera BS; Olivier K; Morris CG; Lynch JW; Mendenhall NP
Am J Clin Oncol; 2007 Dec; 30(6):601-6. PubMed ID: 18091054
[TBL] [Abstract][Full Text] [Related]
45. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
Molin D; Linderoth J; Wahlin BE
Br J Haematol; 2017 May; 177(3):449-456. PubMed ID: 28233899
[TBL] [Abstract][Full Text] [Related]
46. Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
Goel A; Fan W; Patel AA; Devabhaktuni M; Grossbard ML
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):261-70. PubMed ID: 24650975
[TBL] [Abstract][Full Text] [Related]
47. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS; Advani RH
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
[TBL] [Abstract][Full Text] [Related]
48. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
49. Nodular lymphocyte predominant Hodgkin lymphoma: Clincopathological study of 25 cases from Japan with a reappraisal of tissue associated macrophages.
Eladl AE; Satou A; Elsayed AA; Suzuki Y; Shimizu-Kohno K; Kato S; Tomita A; Kinoshita T; Nakamura S; Asano N
Pathol Int; 2015 Dec; 65(12):652-60. PubMed ID: 26538151
[TBL] [Abstract][Full Text] [Related]
50. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
51. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
52. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
[TBL] [Abstract][Full Text] [Related]
53. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site.
Cotta CV; Coleman JF; Li S; Hsi ED
Histopathology; 2011 Dec; 59(6):1194-203. PubMed ID: 22175899
[TBL] [Abstract][Full Text] [Related]
54. Nodular lymphocyte-predominant Hodgkin lymphoma.
Savage KJ; Mottok A; Fanale M
Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
[TBL] [Abstract][Full Text] [Related]
55. Long-term follow-up of 2 patients treated with
Golstein SC; Muylle K; Vercruyssen M; Spilleboudt C; de Wind A; Bron D
Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
[TBL] [Abstract][Full Text] [Related]
56. Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data.
Shivarov V; Ivanova M
Br J Haematol; 2018 Sep; 182(5):727-730. PubMed ID: 28737250
[No Abstract] [Full Text] [Related]
57. The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: a propensity score-matched analysis of the SEER database.
Wang S; Jia M; Han J; Zhang R; Huang K; Qiao Y; Chen P; Fu Z
Cancer Med; 2021 Jan; 10(2):540-551. PubMed ID: 33249743
[TBL] [Abstract][Full Text] [Related]
58. Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy.
Solanki AA; LeMieux MH; Chiu BC; Mahmood U; Hasan Y; Koshy M
PLoS One; 2013; 8(9):e75336. PubMed ID: 24058675
[TBL] [Abstract][Full Text] [Related]
59. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
Ali S; Olszewski AJ
Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
[TBL] [Abstract][Full Text] [Related]
60. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.
Porrata LF; Ristow K; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
Br J Haematol; 2012 May; 157(3):321-30. PubMed ID: 22360654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
